Norma Biln is a leading figure in the Biotechnology sector recently recognized as one of Canada’s Most Powerful Women: Top 100 Award Winner in 2017, and BC’s Most Influential Women 2018: STEM Stars. Throughout her 24 years in the life sciences she has worked along, built and led teams that have consistently exceeded corporate goals. Norma began her career in clinical research with Pfizer Pharmaceuticals after completing her Bachelor of Science in Physiology at McGill University. She continued her career in several capacities in sales management, marketing and market access with Pfizer Pharmaceuticals, Amgen and Abbott Laboratories.
Before her role of CEO at Augurex, Norma worked in various senior management roles in Business Development, Commercial and Communications. She holds a Master of Business Administration and is pursuing her Doctorate, part-time at UBC’s School of Population and Public Health. Norma is a member of the Board of Directors of Resverlogix Corp (TSX:RVX), BIOTECanada, the national industry association and New Ventures BC, the province’s premiere tech competition and early-stage accelerator.